Cytokine Il Articles & Analysis
6 news found
Data showed no dose-limiting toxicities, GvHD or CAR T-related encephalopathy syndrome (CRES). There was one Grade 1 cytokine release syndrome (CRS) event and three patients experienced Grade 3 or 4 treatment-related blood disorders. ...
” Phase 1 Dose-escalation Efficacy Data The Phase 1 clinical trial in relapsed / refractory BCL is assessing FT516 in an off-the-shelf treatment regimen of up to two cycles, with each cycle consisting of three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine), a single-dose of rituximab (375 mg/m2), and three weekly doses of FT516 each with ...
“B244’s downregulation of multiple cytokines such as IL-4, 5, 13, and 31 supports real hope that there will be an effective solution to help stop the itch scratch cycle in both adult and younger populations” said Klaus Dugi, non-executive Director of AOBiome and Adjunct Professor of Medicine at Heidelberg University in Germany. ...
The impetus for the new eczema study was to better understand AOBiome’s recently published data regarding the link between AOB in both a metabolically active and inactive state and the reduction of the itch-related cytokines IL-4 and IL-13. This study further bolsters the assessment of AOB as it relates to their current 576 patient Phase 2b ...
Featured products: Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), SV40-GFP Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-Dsred Reporter-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-luciferase · Cytokine-expressing Oncolytic Virus Research has shown that the oncolytic efficacy of OVs can be ...
The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6. KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and ...